Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics

FASEB Journal

Volumn 31, Issue 6, 2017, Pages 2696-2708

  Vorrink, Sabine U ^a   Ullah, Shahid ^a   Schmidt, Staffan ^a   Nandania, Jatin ^b   Velagapudi, Vidya ^b   Beck, Olof ^a   Ingelman Sundberg, Magnus ^a   Lauschke, Volker M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

3D cell culture; Cytochrome P450 enzymes; Drug metabolism; Hepatic metabolism; Mass spectrometry

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; AMODIAQUINE; AROMATIC HYDROCARBON RECEPTOR; BILE ACID; BILE SALT EXPORT PUMP; CELL NUCLEUS RECEPTOR; CHOLIC ACID; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEETHYLAMODIAQUINE; DEXTROMETHORPHAN; DEXTRORPHAN; GLYCOCHOLIC ACID; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HYDROXYTOLBUTAMIDE; MIDAZOLAM; PARACETAMOL; PHENACETIN; PREGNANE X RECEPTOR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TAUROCHOLIC ACID; TOLBUTAMIDE; XENOBIOTIC AGENT;

ADULT; ARTICLE; CELL CULTURE; CELL DEDIFFERENTIATION; CONTROLLED STUDY; DRUG INDUSTRY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION PROFILING; HEPATIC CLEARANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER METABOLISM; MALE; MASS SPECTROMETRY; METABOLIC STABILITY; METABOLOMICS; MIDDLE AGED; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SPHEROID CELL; STEM CELL; TIME-DEPENDENT INHIBITION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UREA CYCLE; CELL CULTURE TECHNIQUE; CELL LINE; DEVICES; DRUG EFFECTS; GENE EXPRESSION REGULATION; PHYSIOLOGY; PROCEDURES;

CELL CULTURE TECHNIQUES; CELL LINE; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; METABOLOMICS; XENOBIOTICS;

EID: 85020272077     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201601375R     Document Type: Article

References (70)

1. Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., and Olafsson, S. (2013) Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144, 1419-1425. e3; quiz e19-e20
2. Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C., Guilleminet, C., Lenoir, C., Lemoine, A., and Hillon, P. (2002) Incidenceofdrug-induced hepatic injuries: a French population-based study. Hepatology 36, 451-455
3. Björnsson, E., and Olsson, R. (2005) Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42, 481-489
4. Marudanayagam, R., Shanmugam, V., Gunson, B., Mirza, D. F., Mayer, D., Buckels, J., and Bramhall, S. R. (2009) Aetiology and outcome of acute liver failure. HPB (Oxford) 11, 429-434
5. Reuben, A., Koch, D. G., and Lee, W. M.; Acute Liver Failure Study Group. (2010) Drug-induced acute liver failure: results of a U. S. multicenter, prospective study. Hepatology 52, 2065-2076
6. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., and Pangalos, M. N. (2014) Lessons learned from the fate of Astra Zeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419-431
7. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., and Bor, D. H. (2002) Timing ofnew black boxwarnings and withdrawals for prescription medications. JAMA 287, 2215-2220
8. Tufts Center for the Study of Drug Development (2014, November 18). How the Tufts Center for the Study of Drug Development pegged the cost of a new drug at $2.6 billion. Retrieved November 28, 2016, from http://csdd.tufts.edu/files/uploads/cost-study-backgrounder.pdf
9. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Dorato, M., Van Deun, K., Smith, P., Berger, B., and Heller, A. (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67
10. Martignoni, M., Groothuis, G. M. M., and DeKanter, R. (2006) Species differences between mouse, rat, dog, monkey and human CYPmediated drug metabolism, inhibition and induction. Expert Opinion on Drug Metabolism. Toxicology 2, 875-894
11. Gómez-Lechón, M. J., Tolosa, L., Conde, I., and Donato, M. T. (2014) Competency of different cell models to predict human hepatotoxic drugs. Exp. Opin. Drug Metab. Toxicol. 10, 1553-1568
12. Rowe, C., Gerrard, D. T., Jenkins, R., Berry, A., Durkin, K., Sundstrom, L., Goldring, C. E., Park, B. K., Kitteringham, N. R., Hanley, K. P., and Hanley, N. A. (2013) Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation. Hepatology 58, 799-809
13. Azimifar, S. B., Nagaraj, N., Cox, J., and Mann, M. (2014) Cell-type-resolved quantitative proteomics of murine liver. Cell Metab. 20, 1076-1087
14. Lauschke, V. M., Vorrink, S. U., Moro, S. M. L., Rezayee, F., Nordling, Å., Hendriks, D. F. G., Bell, C. C., Sison-Young, R., Park, B. K., Goldring, C. E., Ellis, E., Johansson, I., Mkrtchian, S., Andersson, T. B., and Ingelman-Sundberg, M. (2016) Massive rearrangements of cellular Micro RNA signatures are key drivers of hepatocyte dedifferentiation. Hepatology 64, 1743-1756
15. Sison-Young, R. L., Lauschke, V. M., Johann, E., Alexandre, E., Anthérieu, S., Aerts, H., Gerets, H. H. J., Labbe, G., Höet, D., Dorau, M., Schofield, C. A., Lovatt, C. A., Holder, J. C., Stahl, S. H., Richert, L., Kitteringham, N. R., Jones, R. P., Elmasry, M., Weaver, R. J., Hewitt, P. G., Ingelman-Sundberg, M., Goldring, C. E., and Park, B. K. (2017) A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. Arch. Toxicol. 91, 1385-1400
16. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., and Rosenthal, J. (2014) Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40-51
17. Ware, B. R., and Khetani, S. R. (2016) Engineered Liver Platforms for Different Phases of Drug Development. Trends Biotechnol. 35, 172-183
18. Lauschke, V. M., Hendriks, D. F. G., Bell, C. C., Andersson, T. B., and Ingelman-Sundberg, M. (2016) Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Chem. Res. Toxicol. 29, 1936-1955
19. Tostões, R. M., Leite, S. B., Serra, M., Jensen, J., Björquist, P., Carrondo, M. J. T., Brito, C., and Alves, P. M. (2012) Human liver cell spheroids inextended perfusion bioreactor culture for repeated-dose drug testing. Hepatology 55, 1227-1236
20. Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., Sison-Young, R. L., Jenkins, R. E., Nordling, Å., Mkrtchian, S., Park, B. K., Kitteringham, N. R., Goldring, C. E. P., Lauschke, V. M., and Ingelman-Sundberg, M. (2016) Characterization of primary humanhepatocyte spheroids as amodel systemfor drug-inducedliver injury, liver function and disease. Sci. Rep. 6, 25187
21. Bell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., and Ingelman-Sundberg, M. (2017) Transcriptional, functional and mechanistic comparisons of stem cell-derived hepatocytes, Hepa RG cells and 3D human hepatocyte spheroids as predictive in vitro systems for drug-induced liver injury. [E-pub ahead of print]. Drug Metab. Dispos.
22. McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., and Luciano, C., et al. (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 333, 1099-1105
23. Manning, F. J., and Swartz, M. (1995) Review of the Fialuridine (FIAU) Clinical Trials, National Academies Press, Washington, DC
24. Bowsher, R. R., Compton, J. A., Kirkwood, J. A., Place, G. D., Jones, C. D., Mabry, T. E., Hyslop, D. L., Hatcher, B. L., and DeSante, K. A. (1994) Sensitive andspecific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers. Antimicrob. Agents Chemother. 38, 2134-2142
25. Spaggiari, D., Geiser, L., Daali, Y., and Rudaz, S. (2014) A cocktail approachfor assessing theinvitro activity of humancytochrome P450s: an overview of current methodologies. J. Pharm. Biomed. Anal. 101, 221-237
26. Zhou, J., and Yin, Y. (2016) Strategies for large-scale targeted metabolomics quantification by liquid chromatography-mass spectrometry. Analyst (Lond.) 141, 6362-6373
27. Henry, H., Sobhi, H. R., Scheibner, O., Bromirski, M., Nimkar, S. B., and Rochat, B. (2012) Comparison between a high-resolution singlestage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun. Mass Spectrom. 26, 499-509
28. Eliuk, S., and Makarov, A. (2015) Evolution of Orbitrap Mass Spectrometry Instrumentation. Annu. Rev. Anal. Chem. (Palo Alto, Calif.) 8, 61-80
29. Watson, M., Roulston, A., Bélec, L., Billot, X., Marcellus, R., Bédard, D., Bernier, C., Branchaud, S., Chan, H., Dairi, K., Gilbert, K., Goulet, D., Gratton, M. O., Isakau, H., Jang, A., Khadir, A., Koch, E., Lavoie, M., Lawless, M., Nguyen, M., Paquette, D., Turcotte, E., Berger, A., Mitchell, M., Shore, G. C., and Beauparlant, P. (2009) The small molecule GMX1778is a potent inhibitor of NAD+biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyl transferase 1-deficient tumors. Mol. Cell. Biol. 29, 5872-5888
30. Tiziani, S., Lodi, A., Khanim, F. L., Viant, M. R., Bunce, C. M., and Günther, U. L. (2009) Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS One 4, e4251
31. Wang, Y., Gao, D., Chen, Z., Li, S., Gao, C., Cao, D., Liu, F., Liu, H., and Jiang, Y. (2013) Acridone derivative 8a induces oxidative stress-mediated apoptosis in CCRF-CEM leukemia cells: application of metabolomics in mechanistic studies of antitumor agents. PLoS One 8, e63572-e63579
32. Krauss, R. M., Zhu, H., and Kaddurah-Daouk, R. (2013) Pharma cometabolomics of statin response. Clin. Pharmacol. Ther. 94, 562-565
33. Roman-Garcia, P., Quiros-Gonzalez, I., Mottram, L., Lieben, L., Sharan, K., Wangwiwatsin, A., Tubio, J., Lewis, K., Wilkinson, D., Santhanam, B., Sarper, N., Clare, S., Vassiliou, G. S., Velagapudi, V. R., Dougan, G., and Yadav, V. K. (2014) Vitamin B12-dependent taurine synthesis regulates growth and bone mass. J. Clin. Invest. 124, 2988-3002
34. Vrzal, R., Stejskalova, L., Monostory, K., Maurel, P., Bachleda, P., Pavek, P., and Dvorak, Z. (2009) Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes. Chem. Biol. Interact. 179, 288-296
35. Yoshinari, K., Yoda, N., Toriyabe, T., and Yamazoe, Y. (2010) Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes througha commonregulatory element in the 59-flanking region. Biochem. Pharmacol. 79, 261-269
36. Shan, J., Schwartz, R. E., Ross, N. T., Logan, D. J., Thomas, D., Duncan, S. A., North, T. E., Goessling, W., Carpenter, A. E., and Bhatia, S. N. (2013) Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat. Chem. Biol. 9, 514-520
37. Oshiro, C., Mangravite, L., Klein, T., and Altman, R. (2010) PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet. Genomics 20, 211-216
38. Maglich, J. M., Parks, D. J., Moore, L. B., Collins, J. L., Goodwin, B., Billin, A. N., Stoltz, C. A., Kliewer, S. A., Lambert, M. H., Willson, T. M., and Moore, J. T. (2003) Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J. Biol. Chem. 278, 17277-17283
39. Ihunnah, C. A., Jiang, M., and Xie, W. (2011) Nuclear receptor PXR, transcriptional circuits and metabolic relevance. BBA-Molecular Basis of Disease 1812, 956-963
40. Jones, D. R., Gorski, J. C., Haehner, B. D., O'Mara, E. M., Jr., and Hall, S. D. (1996) Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin. Pharmacol. Ther. 60, 374-384
41. Houtkooper, R. H., Cantó, C., Wanders, R. J., and Auwerx, J. (2010) The secret life of NAD+: an oldmetabolite controlling newmetabolic signaling pathways. Endocr. Rev. 31, 194-223
42. Inoue, Y., Yu, A.-M., Yim, S. H., Ma, X., Krausz, K. W., Inoue, J., Xiang, C. C., Brownstein, M. J., Eggertsen, G., Björkhem, I., and Gonzalez, F. J. (2006) Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J. Lipid Res. 47, 215-227
43. Kir, S., Zhang, Y., Gerard, R. D., Kliewer, S. A., and Mangelsdorf, D. J. (2012) Nuclear receptors HNF4a and LRH-1 cooperate in regulating Cyp7a1 in vivo. J. Biol. Chem. 287, 41334-41341
44. Hayes, K. C., and Sturman, J. A. (1981) Taurine inmetabolism. Annu. Rev. Nutr. 1, 401-425
45. Chapman, K. L., Holzgrefe, H., Black, L. E., Brown, M., Chellman, G., Copeman, C., Couch, J., Creton, S., Gehen, S., Hoberman, A., Kinter, L. B., Madden, S., Mattis, C., Stemple, H. A., and Wilson, S. (2013) Pharmaceutical toxicology: designing studies to reduce animal use, while maximizing human translation. Regul. Toxicol. Pharmacol. 66, 88-103
46. Ferguson, S. S., Chen, Y., LeCluyse, E. L., Negishi, M., and Goldstein, J. A. (2005) Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol. Pharmacol. 68, 747-757
47. Sahi, J., Shord, S. S., Lindley, C., Ferguson, S., and LeCluyse, E. L. (2009) Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J. Biochem. Mol. Toxicol. 23, 43-58
48. Goodwin, B., Hodgson, E., and Liddle, C. (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329-1339
49. Sugatani, J., Nishitani, S., Yamakawa, K., Yoshinari, K., Sueyoshi, T., Negishi, M., and Miwa, M. (2005) Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptormediated UDP-glucuronosyl transferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol. Pharmacol. 67, 845-855
50. Renwick, A. B., Watts, P. S., Edwards, R. J., Barton, P. T., Guyonnet, I., Price, R. J., Tredger, J. M., Pelkonen, O., Boobis, A. R., and Lake, B. G. (2000) Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos. 28, 1202-1209
51. Maurel, P. (1996) The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv. Drug Deliv. Rev. 22, 105-132
52. Venkatakrishnan, K., and Obach, R. S. (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab. Dispos. 33, 845-852
53. Schmid, B., Bircher, J., Preisig, R., and Küpfer, A. (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther. 38, 618-624
54. Lauschke, V. M., and Ingelman-Sundberg, M. (2016) The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. Int. J. Mol. Sci. 17, E1714
55. Ranninger, C., Schmidt, L. E., Rurik, M., Limonciel, A., Jennings, P., Kohlbacher, O., and Huber, C. G. (2016) Improving global feature detectabilities through scan range splitting for untargeted metabolomics by high-performance liquid chromatography-Orbitrap mass spectrometry. Anal. Chim. Acta 930, 13-22
56. Najdekr, L., Friedecký, D., Tautenhahn, R., Pluskal, T., Wang, J., Huang, Y., and Adam, T. (2016) Influence ofmass resolving power in orbital ion-trap mass spectrometry-based metabolomics. Anal. Chem. 88, 11429-11435
57. Cajka, T., and Fiehn, O. (2016) Toward Merging Untargeted and Targeted Methods in Mass Spectrometry-Based Metabolomics and Lipidomics. Anal. Chem. 88, 524-545
58. Roe, B., Kensicki, E., Mohney, R., and Hall, W. W. (2011) Metabolomic profile of hepatitis C virus-infected hepatocytes. PLoS One 6, e23641
59. Meissen, J. K., Hirahatake, K. M., Adams, S. H., and Fiehn, O. (2015) Temporal metabolomic responses of cultured HepG2 liver cells to high fructose and high glucose exposures. Metabolomics 11, 707-721
60. García-Cañaveras, J. C., Castell, J. V., Donato, M. T., and Lahoz, A. (2016) A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury. Sci. Rep. 6, 27239
61. Brown, M. V., Compton, S. A., Milburn, M. V., Lawton, K. A., and Cheatham, B. (2013) Metabolomic signatures in lipid-loaded Hepa RGs reveal pathways involved in steatotic progression. Obesity (Silver Spring) 21, E561-E570
62. Vanden Eede, N., Cuykx, M., Rodrigues, R. M., Laukens, K., Neels, H., Covaci, A., and Vanhaecke, T. (2015) Metabolomics analysis of the toxicity pathways of triphenyl phosphate in HepaRG cells and comparison to oxidative stress mechanisms caused by acetaminophen. Toxicol. In Vitro 29, 2045-2054
63. Jeon, S.-M. (2016) Regulation and function of AMPK in physiology and diseases. Exp. Mol. Med. 48, e245
64. Häberle, J., Boddaert, N., Burlina, A., Chakrapani, A., Dixon, M., Huemer, M., Karall, D., Martinelli, D., Crespo, P. S., Santer, R., Servais, A., Valayannopoulos, V., Lindner, M., Rubio, V., and Dionisi-Vici, C. (2012) Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J. Rare Dis. 7, 32
65. Kim, S.-R., Kubo, T., Kuroda, Y., Hojyo, M., Matsuo, T., Miyajima, A., Usami, M., Sekino, Y., Matsushita, T., and Ishida, S. (2014) Comparative metabolome analysis of cultured fetal and adult hepatocytes in humans. J. Toxicol. Sci. 39, 717-723
66. Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C., and Guguen-Guillouzo, C. (2002) Infection of ahuman hepatoma cell line by hepatit is Bvirus. Proc. Natl. Acad. Sci. USA 99, 15655-15660
67. Kanebratt, K. P., and Andersson, T. B. (2008) Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 36, 1444-1452
68. Anthérieu, S., Chesné, C., Li, R., Camus, S., Lahoz, A., Picazo, L., Turpeinen, M., Tolonen, A., Uusitalo, J., Guguen-Guillouzo, C., and Guillouzo, A. (2010) Stable expression, activity, and inducibility of cytochromes P450 in differentiat ed Hepa RG cells. Drug Metab. Dispos. 38, 516-525
69. Baxter, M., Withey, S., Harrison, S., Segeritz, C.-P., Zhang, F., Atkinson-Dell, R., Rowe, C., Gerrard, D. T., Sison-Young, R., Jenkins, R., Henry, J., Berry, A. A., Mohamet, L., Best, M., Fenwick, S. W., Malik, H., Kitteringham, N. R., Goldring, C. E., Piper Hanley, K., Vallier, L., and Hanley, N. A. (2015) Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. J. Hepatol. 62, 581-589
70. Yu, A., and Haining, R. L. (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab. Dispos. 29, 1514-1520